Bio-producing bacterial cellulose filaments through co-designing with biological characteristics

The need for circular textiles has led to an interest in the production of biologically derived materials, generating new research into the bioproduction of textiles through design and interdisciplinary approaches. Bacterial cellulose has been produced directly from fermentation into sheets but not yet investigated in terms of producing filaments directly from fermentation. This leaves a wealth of material qualities unexplored. Further, by growing the material directly into filaments, production such as wet spinning are made redundant, thus reducing textile manufacturing steps. The aim of this study was to grow the bio-material, namely bacterial cellulose directly into a filament. This was achieved using a method of co-designing with the characteristics of biological materials. The method combines approaches of material-driven textile design and human-centred co-design to investigate co-designing with the characteristics of living materials for biological material production. The project is part of a wider exploration of bio-manufacturing textiles from waste. The practice-based approach brought together biological sciences and material design through a series of iterative experiments. This, in turn, resulted in designing with the inherent characteristics of bacterial cellulose, and by doing so filaments were designed to be fabricated directly from fermentation. In this investigation, creative exploration was encouraged within a biological laboratory space, showing how interdisciplinary collaboration can offer innovative alternative bioproduction routes for textile filament production

Mechanical, chemical, biological : Moving towards closed-loop bio-based recycling in a circular economy of sustainable textiles

The textile industry is facing increasing criticism because of its intensive use of resources –both natural and fossil derived– and the negative environmental and societal impacts associated with the manufacturing, use and disposal of clothes. This has led to a desire to move towards a circular economy for textiles that will implement recycling concepts and technologies to protect resources, the environment and people. So far, recycling processes have been focused on the chemical and mechanical reuse of textile fibres. In contrast, bio-based processes for textile production and recycling have received little attention, beyond end-of-life composting. However, the selectivity and benign processing conditions associated with bio-based technologies hold great promise for circularising the textile life cycle and reducing the environmental impacts of textile production and processing. Developing circular and sustainable systems for textile production requires a revolutionary system approach that encompasses the choice of material and finishes being designed for recycling at the end of life, and in this context bio-based processes can help provide the means to maintain materials in a closed loop. This paper reviews established methods in mechanical and chemical recycling processes in closed-loop textile recycling of all fibre types, as well as bio-based processes that demonstrate open-loop textile recycling. Fermentation and enzymatic processes have been demonstrated for the production of all types of textiles, which in combination with enzymatic deconstruction of end of life cellulosic textiles could allow them to be recycled indefinitely. Within the context of the circular economy, bio-based processes could extend mechanical and chemical textile recycling mechanisms in the technical cycle, enabling greater circularity of textiles in the biological cycle before composting takes place

Simple, quick and green isolation of cannabinoids from complex natural product extracts using sustainable mesoporous materials (Starbon®)

The current process to purify CBD from C. sativa extract is long and intensive, requiring several steps such as winterification for 48 hours at -45 °C and high-temperature, high vacuum distillation. These processes are capital intensive and generate large amounts of toxic solvent waste. In contrast, the solid phase extraction (SPE) methodology proposed herein will change the way CBD is obtained, doing so in a single step that is fast and reusable. Furthermore, the new process is simple and easily implemented and does not require any intensive operator training. Starbon® A300 was successfully employed as the stationary phase in SPE taking Cannabis sativa extract in hexane to selectively physisorb the cannabinoids onto the surface, followed by ethanol to bring about desorption at up to 93% (by GC-FID). A similar one pot system was also proven, using Fedora hemp stem dust as feedstock, with extraction and adsorption in supercritical CO2 followed by desorption in ethanol

Utilisation of supercritical fluids for the effective extraction of waxes and Cannabidiol (CBD) from hemp wastes

Up to 33% of hemp by mass can be lost in the form of dust during processing for fibre production. Heptane Soxhlet extractions and supercritical carbon dioxide extractions (scCO2) of hemp dust samples yielded significant quantities of high value lipophilic molecules including fatty acids, policosanols (fatty alcohols), fatty aldehydes, hydrocarbons, sterols, triterpenoids and cannabinoids (cannabidiol (CBD)). Dust collected from different stages of the mechanical processing of hemp fibres gave rise to lipophilic extractives with varying compositions, thus making the isolation and purification of these compounds easier. Of particular interest is CBD (5832.5 ± 118.9 μg/g of dust), which has attracted much attention for clinical-level studies due to its therapeutic efficacy in the treatment of a variety of central nervous system (CNS) disorders. Factorial experimental design was carried out to optimise the scCO2 extraction, with 350 bar and 50 °C yielding the selective extraction of higher value components

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

International audienceBackground: Various observations have suggested that the course of COVID-19 might be less favourable in patients with inflammatory rheumatic and musculoskeletal diseases receiving rituximab compared with those not receiving rituximab. We aimed to investigate whether treatment with rituximab is associated with severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases.Methods: In this cohort study, we analysed data from the French RMD COVID-19 cohort, which included patients aged 18 years or older with inflammatory rheumatic and musculoskeletal diseases and highly suspected or confirmed COVID-19. The primary endpoint was the severity of COVID-19 in patients treated with rituximab (rituximab group) compared with patients who did not receive rituximab (no rituximab group). Severe disease was defined as that requiring admission to an intensive care unit or leading to death. Secondary objectives were to analyse deaths and duration of hospital stay. The inverse probability of treatment weighting propensity score method was used to adjust for potential confounding factors (age, sex, arterial hypertension, diabetes, smoking status, body-mass index, interstitial lung disease, cardiovascular diseases, cancer, corticosteroid use, chronic renal failure, and the underlying disease [rheumatoid arthritis vs others]). Odds ratios and hazard ratios and their 95% CIs were calculated as effect size, by dividing the two population mean differences by their SD. This study is registered with ClinicalTrials.gov, NCT04353609.Findings: Between April 15, 2020, and Nov 20, 2020, data were collected for 1090 patients (mean age 55·2 years [SD 16·4]); 734 (67%) were female and 356 (33%) were male. Of the 1090 patients, 137 (13%) developed severe COVID-19 and 89 (8%) died. After adjusting for potential confounding factors, severe disease was observed more frequently (effect size 3·26, 95% CI 1·66-6·40, p=0·0006) and the duration of hospital stay was markedly longer (0·62, 0·46-0·85, p=0·0024) in the 63 patients in the rituximab group than in the 1027 patients in the no rituximab group. 13 (21%) of 63 patients in the rituximab group died compared with 76 (7%) of 1027 patients in the no rituximab group, but the adjusted risk of death was not significantly increased in the rituximab group (effect size 1·32, 95% CI 0·55-3·19, p=0·53).Interpretation: Rituximab therapy is associated with more severe COVID-19. Rituximab will have to be prescribed with particular caution in patients with inflammatory rheumatic and musculoskeletal diseases

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

International audienceObjectives: There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated with severe disease, then with death. We also compared mortality between patients hospitalised for COVID-19 with and without iRMD.Methods: Individuals with suspected iRMD-COVID-19 were included in this French cohort. Logistic regression models adjusted for age and sex were used to estimate adjusted ORs and 95% CIs of severe COVID-19. The most significant clinically relevant factors were analysed by multivariable penalised logistic regression models, using a forward selection method. The death rate of hospitalised patients with iRMD-COVID-19 (moderate-severe) was compared with a subset of patients with non-iRMD-COVID-19 from a French hospital matched for age, sex, and comorbidities.Results: Of 694 adults, 438 (63%) developed mild (not hospitalised), 169 (24%) moderate (hospitalised out of the intensive care unit (ICU) and 87 (13%) severe (patients in ICU/deceased) disease. In multivariable imputed analyses, the variables associated with severe infection were age (OR=1.08, 95% CI: 1.05-1.10), female gender (OR=0.45, 95% CI: 0.25-0.80), body mass index (OR=1.07, 95% CI: 1.02-1.12), hypertension (OR=1.86, 95% CI: 1.01-3.42), and use of corticosteroids (OR=1.97, 95% CI: 1.09-3.54), mycophenolate mofetil (OR=6.6, 95% CI: 1.47-29.62) and rituximab (OR=4.21, 95% CI: 1.61-10.98). Fifty-eight patients died (8% (total) and 23% (hospitalised)). Compared with 175 matched hospitalised patients with non-iRMD-COVID-19, the OR of mortality associated with hospitalised patients with iRMD-COVID-19 was 1.45 (95% CI: 0.87-2.42) (n=175 each group).Conclusions: In the French RMD COVID-19 cohort, as already identified in the general population, older age, male gender, obesity, and hypertension were found to be associated with severe COVID-19. Patients with iRMD on corticosteroids, but not methotrexate, or tumour necrosis factor alpha and interleukin-6 inhibitors, should be considered as more likely to develop severe COVID-19. Unlike common comorbidities such as obesity, and cardiovascular or lung diseases, the risk of death is not significantly increased in patients with iRMD

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

International audienceObjectives: There is little known about the impact of SARS-CoV-2 on patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). We examined epidemiological characteristics associated with severe disease, then with death. We also compared mortality between patients hospitalised for COVID-19 with and without iRMD.Methods: Individuals with suspected iRMD-COVID-19 were included in this French cohort. Logistic regression models adjusted for age and sex were used to estimate adjusted ORs and 95% CIs of severe COVID-19. The most significant clinically relevant factors were analysed by multivariable penalised logistic regression models, using a forward selection method. The death rate of hospitalised patients with iRMD-COVID-19 (moderate-severe) was compared with a subset of patients with non-iRMD-COVID-19 from a French hospital matched for age, sex, and comorbidities.Results: Of 694 adults, 438 (63%) developed mild (not hospitalised), 169 (24%) moderate (hospitalised out of the intensive care unit (ICU) and 87 (13%) severe (patients in ICU/deceased) disease. In multivariable imputed analyses, the variables associated with severe infection were age (OR=1.08, 95% CI: 1.05-1.10), female gender (OR=0.45, 95% CI: 0.25-0.80), body mass index (OR=1.07, 95% CI: 1.02-1.12), hypertension (OR=1.86, 95% CI: 1.01-3.42), and use of corticosteroids (OR=1.97, 95% CI: 1.09-3.54), mycophenolate mofetil (OR=6.6, 95% CI: 1.47-29.62) and rituximab (OR=4.21, 95% CI: 1.61-10.98). Fifty-eight patients died (8% (total) and 23% (hospitalised)). Compared with 175 matched hospitalised patients with non-iRMD-COVID-19, the OR of mortality associated with hospitalised patients with iRMD-COVID-19 was 1.45 (95% CI: 0.87-2.42) (n=175 each group).Conclusions: In the French RMD COVID-19 cohort, as already identified in the general population, older age, male gender, obesity, and hypertension were found to be associated with severe COVID-19. Patients with iRMD on corticosteroids, but not methotrexate, or tumour necrosis factor alpha and interleukin-6 inhibitors, should be considered as more likely to develop severe COVID-19. Unlike common comorbidities such as obesity, and cardiovascular or lung diseases, the risk of death is not significantly increased in patients with iRMD